IBTK and myeloid sarcoma: The interest in BTKi as a rational, non-depleting B-cell targeted therapeutic option for treatment of MS stems from BTK’s role in BCR and other innate immune cell intracellular signaling pathways, expression in various cells of hematopoietic origin and in CNS-resident innate microglia and astrocytes.